Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common mucus-thinning drugs may improve outcomes in COPD patients with lung cancer

NCT ID NCT07712016

Knowledge-focused Sponsor: Seoul National University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 22, 2026 · Updated 2 times

Summary

This study looks at whether taking muco-active agents (mucus-thinning drugs like N-acetylcysteine and ambroxol) after a lung cancer diagnosis is linked to better outcomes in people who also have COPD. Researchers will analyze data from a large Korean database, comparing those who started these drugs shortly after diagnosis to those who did not. The main focus is on whether these drugs reduce the risk of moderate-to-severe COPD flare-ups and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
muco-active agents (mucolytics, expectorants, and mucokinetics such as N-acetylcysteine, erdosteine, carbocysteine, guaifenesin, ivy-leaf extract, ambroxol, and bromhexine)
What this could lead to
If the study finds a link, it could suggest that using these common mucus-thinning drugs after a lung cancer diagnosis might help people with COPD have fewer flare-ups and live longer.
What could go wrong
This is an observational study using existing data, not a controlled experiment. It can only show an association, not prove cause and effect, and results may be influenced by unmeasured differences between groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 27,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include adults aged 40 to 79 years with chronic obstructive pulmonary disease (COPD) diagnosed before newly diagnosed localized-stage lung cancer in the Korean Cancer Data Center (K-CURE) database from January 1, 2002, to December 31, 2023. Eligibility will be determined using prespecified diagnostic, treatment, prescription, procedure, washout, and follow-up criteria. Patients who used muco-active agents during the 12-week washout period before lung cancer diagnosis will be excluded to support a new-user design. Treatment strategies and outcomes will be identified using prescription, clinical, and mortality records.

Ages

40 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 40 to 79 years. * Diagnosis of chronic obstructive pulmonary disease before lung cancer diagnosis. * Newly diagnosed localized-stage lung cancer. * Stable COPD and lung cancer treatment regimen at baseline. * Eligible for one of the predefined treatment strategies. * Available baseline information and follow-up data. Exclusion Criteria: * Asthma or bronchiectasis. * Long-term oxygen therapy. * Severe medical comorbidities defined in the protocol. * Neurologic diseases affecting prognosis. * Muco-active agent use during the 12-week washout period. * Missing essential baseline variables.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset disease Disease Progression lung cancer lung disorder lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD) COPD, chronic obstructive pulmonary disease Lung cancer (diagnosis)

Contacts and locations

Locations

  • National Cancer Center,

    Goyang-si, Gyeonggi-do, 10408, South Korea

  • Seoul National University College of Medicine, Seoul Metropolitan Government-Seoul National University Boramae Medical Center

    Seoul, Select..., 07061, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.